Literature DB >> 1382167

Angiotensin-converting enzyme inhibition, angiotensin, and cognition.

J M Barnes1, N M Barnes, B Costall, J Coughlan, M E Kelly, R J Naylor, D M Tomkins, T J Williams.   

Abstract

In these studies, we have investigated possible cognition-enhancing effects of angiotensin-converting enzyme (ACE) inhibition, and putative neurochemical correlates for these actions. In a mouse habituation model, ACE inhibitors improved basal performance and antagonized scopolamine-induced deficits. The performance of aged mice and those with lesions of the nucleus basalis was also improved. ACE inhibition also improved scopolamine-impaired performance of rats in a swim-maze model. Neurochemical studies showed that a low dose (10 micrograms/kg i.p.) of ceranapril caused significant alterations in ex vivo rat brain catecholamine levels in the nucleus accumbens, amygdala, and septum. In further studies, angiotensin II (Ang II) was shown to decrease potassium-stimulated [3H] acetylcholine release from slices of rat entorhinal and human temporal cortex, an effect that could be antagonized by the angiotensin receptor antagonist [1-sar,8-thr]Ang II. It is concluded that ACE inhibition can improve both basal and impaired performance in animal models of learning, and that this improvement may be in part a consequence of the removal by ACE inhibition of an inhibitory tone on central acetylcholine release, and/or an effect on central catecholaminergic function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382167     DOI: 10.1097/00005344-199219006-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  15 in total

1.  Simultaneous analysis of angiotensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells.

Authors:  Lijie Cui; Kasem Nithipatikom; William B Campbell
Journal:  Anal Biochem       Date:  2007-07-05       Impact factor: 3.365

2.  Angiotensin I converting enzyme polymorphism effects in patients with normal pressure hydrocephalus syndrome before and after surgery.

Authors:  Maria del Mar Matarín; Maria Antonia Poca; David Bartrés-Faz; Maria Mataró; Imma C Clemente; Cristina Solé-Padullés; Emili González-Pérez; Pedro Moral; Maite Barrios; Carme Junqué; Juan Sahuquillo
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

3.  The novel nonapeptide acein targets angiotensin converting enzyme in the brain and induces dopamine release.

Authors:  Jérémie Neasta; Charlène Valmalle; Anne-Claire Coyne; Eric Carnazzi; Gilles Subra; Jean-Claude Galleyrand; Didier Gagne; Céline M'Kadmi; Nicole Bernad; Gilbert Bergé; Sonia Cantel; Philippe Marin; Jacky Marie; Jean-Louis Banères; Marie-Lou Kemel; Valérie Daugé; Karine Puget; Jean Martinez
Journal:  Br J Pharmacol       Date:  2016-03-08       Impact factor: 8.739

Review 4.  The effects of ACE inhibitors on cognitive function.

Authors:  A A O'Brien; C J Bulpitt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 5.  Do angiotensin receptor blockers protect against Alzheimer's disease?

Authors:  Hitomi Kurinami; Munehisa Shimamura; Naoyuki Sato; Hironori Nakagami; Ryuichi Morishita
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

Review 6.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

Review 7.  The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease.

Authors:  Chao-Liang Chou; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

8.  Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.

Authors:  D C Brown; L J Steward; J Ge; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

9.  The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene 'knockout' mice: sex differences and implications for the treatment of attention deficit hyperactivity disorder.

Authors:  Ashley J Porter; Katharine Pillidge; Ewelina M Grabowska; S Clare Stanford
Journal:  Eur Neuropsychopharmacol       Date:  2015-02-07       Impact factor: 4.600

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.